Bird&Be secures $13M Series A for fertility health platform
A Toronto-based company offering reproductive health supplements and test kits has closed a $13-million USD Series A round. Bird&Be’s platform focuses on fertility support, providing products directly to consumers. The funding follows its earlier seed round and expands its reach in the growing fertility market.
Sources: betakit.com
“This funding round underscores investor confidence in consumer-facing fertility solutions, a sector that has seen increased attention amid rising demand for accessible reproductive health options.”
What it means
While fertility tech has historically been dominated by clinical or B2B models, Bird&Be’s direct-to-consumer approach reflects a broader shift toward at-home and preventative health solutions. The Series A suggests scalability in this niche, though competition from established players and regulatory scrutiny over health claims could shape its trajectory. Future growth may hinge on clinical validation and partnerships with healthcare providers.
Read the original reporting
The outlets below did the original reporting.
Related briefs
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.